GlassScriptPhysician profile
Tonya Colton
NPI 1467793703
$5,212.47
in general payments reported to CMS, 2019-2025
21 companies · $2,282 in 2025
The $2,282 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.43 · 2022: $155 · 2023: $1,132 · 2024: $1,580 · 2025: $2,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,993.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,117.54 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $631.12 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $512.48 | 2022-2025 | Spravato, Invega Sustenna |
| Corium, LLC | $463.56 | 2023-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $436.60 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $330.13 | 2023-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $244.28 | 2024-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $224.15 | 2023-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Abbvie INC. | $201.60 | 2021-2024 | |
| Collegium Pharmaceutical, INC. | $198.68 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $194.25 | 2023-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $181.89 | 2023-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $143.27 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $99.23 | 2023-2024 | Trintellix |
| Neos Therapeutics, LP | $61.22 | 2024-2025 | Adzenys Xr-Odt |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $57.45 | 2023-2025 | Austedo Xr, Austedo Xr |
| Tris Pharma INC | $43.15 | 2023-2025 | Dyanavel Xr |
| Harmony Biosciences LLC | $22.48 | 2025 | |
| Almatica Pharma LLC | $21.12 | 2024 | Loreev Xr, Teriparatide |
| Idorsia Pharmaceuticals US INC | $14.24 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $14.03 | 2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonya Colton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.